Chardan Capital initiated coverage on shares of Novartis AG (NYSE:NVS) in a report issued on Tuesday. The brokerage issued a buy rating and a $95.00 price target on the stock.

NVS has been the topic of a number of other reports. JPMorgan Chase & Co. restated a buy rating on shares of Novartis AG in a research report on Tuesday, July 19th. TheStreet upgraded shares of Novartis AG from a hold rating to a buy rating in a research report on Friday, June 24th. Argus restated a hold rating on shares of Novartis AG in a research report on Thursday, August 25th. Bank of America Corp. restated a hold rating on shares of Novartis AG in a research report on Tuesday, July 12th. Finally, Zacks Investment Research lowered shares of Novartis AG from a buy rating to a hold rating in a research report on Tuesday, July 12th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Novartis AG currently has an average rating of Hold and an average target price of $91.83.

Shares of Novartis AG (NYSE:NVS) opened at 82.03 on Tuesday. Novartis AG has a 12-month low of $69.90 and a 12-month high of $95.11. The company has a 50 day moving average of $80.75 and a 200-day moving average of $78.38. The company has a market cap of $195.33 billion, a PE ratio of 29.29 and a beta of 0.58.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.05. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. The company had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. During the same quarter last year, the company earned $1.25 earnings per share. Equities research analysts anticipate that Novartis AG will post $4.72 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Primecap Management Co. CA increased its position in shares of Novartis AG by 0.8% in the first quarter. Primecap Management Co. CA now owns 20,938,858 shares of the company’s stock valued at $1,516,811,000 after buying an additional 170,750 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Novartis AG by 22.4% in the first quarter. Franklin Resources Inc. now owns 11,998,737 shares of the company’s stock valued at $869,189,000 after buying an additional 2,195,618 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Novartis AG by 1.2% in the second quarter. Fisher Asset Management LLC now owns 6,363,641 shares of the company’s stock valued at $523,791,000 after buying an additional 76,542 shares during the last quarter. Loomis Sayles & Co. L P increased its position in shares of Novartis AG by 6.8% in the second quarter. Loomis Sayles & Co. L P now owns 5,601,211 shares of the company’s stock valued at $462,156,000 after buying an additional 358,263 shares during the last quarter. Finally, Mawer Investment Management Ltd. increased its position in shares of Novartis AG by 10.4% in the second quarter. Mawer Investment Management Ltd. now owns 3,743,858 shares of the company’s stock valued at $308,906,000 after buying an additional 351,773 shares during the last quarter. 9.78% of the stock is owned by hedge funds and other institutional investors.

About Novartis AG

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.